Please assess the completion status of the following clinical trial:

Trial Title: Proton Radiation Therapy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate adenocarcinoma within 365 days of registration~* Clinical stages T1a-T2a N0 M0~* For any pelvic lymph node \>= 1.5cm, biopsy of the lymph node is mandatory~* Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason score must be in the range 2-6; \> 6 cores is strongly recommended; the highest Gleason score in any core reported on the pathology report will be used for determining inclusion~* PSA values \< 10 ng/ml within 90 days prior to registration, done either prior to prostate biopsy or at least 21 days after prostate biopsy.~* Alkaline phosphatase within 60 days prior to registration. If alkaline phosphatase is elevated \> 2 x the upper limit of institutional normal (UNL), patient must have radiological correlation to assess for metastases~* Zubrod status 0-1 documented within 60 days of registration~* Prior androgen deprivation is allowed; however, androgen deprivation will not be continued concurrently or as an adjuvant therapy~* Patients must give IRB-approved study-specific informed consent~* Patients must complete all required tests listed within the specified time frames~* Patients must be able to start treatment within 56 days of registration~* Members of all races and ethnic groups are eligible for this trial~Exclusion Criteria:~* Clinical stages T2c or greater~* PSA of 10 ng/ml or greater~* Gleason score 7 or higher~* Evidence of distant metastasis~* Evidence of lymph node involvement~* Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery~* Previous pelvic radiation for prostate cancer~* Androgen deprivation therapy prior to radiation is allowed; however, it is not acceptable if continued during radiation or as adjuvant therapy~* Active rectal diverticulitis, Crohn's disease, or ulcerative colitis are not allowed~* Prior systemic chemotherapy for prostate cancer~* History of proximal urethral stricture requiring dilatation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo proton radiotherapy once daily 5 days a week for approximately 9 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).